MELBOURNE, Australia and INDIANAPOLIS, Ind. and LAKE MARY, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) — Telix Prescribed drugs Restricted (ASX: TLX, Telix, the Firm) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America’s solely Joint Fee-accredited radiopharmacy community distributing PET1, SPECT2 and therapeutic radiopharmaceuticals, at the moment introduced an settlement by the Firm to amass RLS from its mum or dad firm, RLS Group Ltd. The acquisition considerably expands Telix’s North American manufacturing footprint and establishes the idea of a subsequent technology radiometal manufacturing community to learn Telix and choose strategic business companions.
Strategic Rationale
The acquisition of RLS is aligned to Telix’s funding technique round vertically built-in provide chain, manufacturing, and distribution, additional enabling the supply of future medical and business radiopharmaceutical merchandise. The Firm views this as a mandatory measure to make sure product integrity and supply, and to strengthen and complement present business partnerships.
Telix will leverage RLS’ 31 licensed radiopharmacies situated in main metropolitan areas throughout the U.S. to construct a radiometal manufacturing and distribution community for key therapeutic and diagnostic isotopes alongside last-mile supply of completed unit doses in related markets. The RLS footprint contains over 100,000 sq. ft of appropriately licensed enlargement house that may be utilized to fulfill quickly rising manufacturing demand. The acquisition additionally gives a transparent pathway to extensively deploy Telix’s AR™S QUAN™ Irradiation System™ (QIS™) cyclotron expertise, enabling standardized, high-efficiency and cost-effective manufacturing of radiometals.
By augmenting its present distribution community, Telix goals to offer further provide chain backup and enhance capability to fulfill future demand, whereas broadening entry for sufferers throughout the whole U.S. market, together with under-served populations. The acquisition aligns Telix’s pharmaceutical improvement workforce with RLS’ extremely expert and multi-disciplinary radiopharmaceutical manufacturing, provide chain and operational experience.
RLS will proceed to service its present clients and function as an impartial enterprise unit beneath Telix Manufacturing Options (™S), which incorporates different key Telix manufacturers with multi-vendor and third-party relationships akin to AR™S, IsoTherapeutics and Optimum Tracers. As a part of the ™S enterprise vertical, RLS will develop into a key node in Telix’s community of U.S. manufacturing and distribution partnerships and is geographically complementary to ™S’ state-of-the-art GMP3 manufacturing facility situated in Belgium.
RLS’ income for FY234 was US$158 million, and the transaction is predicted to be cost-neutral to Telix from an working money movement perspective. RLS is at the moment a distributor of Illuccix ® and, as such, the acquisition is predicted to be accretive to Telix, following completion.
Dr. Christian Behrenbruch, Telix Managing Director and Group Chief Government Officer, mentioned the acquisition is a part of the Firm’s ongoing funding focus round vertical integration and constructing built-in provide chains.
Our imaginative and prescient is to construct a radiometal manufacturing and distribution community match for the longer term. By combining the AR™S platform and the RLS community, we will scale up the manufacturing of key isotopes and construct a steady and constant provide of PET and SPECT diagnostic tracers, together with therapeutic radiopharmaceuticals throughout the U.S. for the good thing about Telix, our companions and the sufferers we serve. Telix is a trusted model, acknowledged for our technical experience, product high quality, scheduling flexibility and supply reliability. As we develop and commercialize new merchandise, this funding ensures we will proceed to ship to this normal, alongside our key trusted distribution companions.
Mr. Stephen Belcher, Chief Government Officer, RLS, added, We look ahead to changing into a part of the Telix Group ecosystem. The RLS administration workforce has emphasised high quality, reliability and adaptability, and by leveraging Telix’s assist, we can develop our capabilities additional and, collectively, construct the radiopharmaceutical firm of the longer term. We see this as a really optimistic step for the corporate, our individuals and our buyer base.
Deal Phrases and Circumstances
The acquisition worth contains upfront money consideration of US$230 million earlier than changes for money and money equivalents (web of restricted money); debt and debt equivalents; transaction bills; and dealing capital, and deferred money consideration as much as a most of US$20 million, contingent on achievement of sure milestones associated to demonstration of accretive monetary and operational efficiency through the four-quarters following closing. The acquisition and associated transaction prices are anticipated to be funded from present money reserves.
Closing of the transaction is topic to customary circumstances, together with regulatory approvals, RLS shareholder approval, licence transfers and sure third-party consents. The acquisition is predicted to shut early within the first quarter of 2025.
About RLS Radiopharmacies
RLS is America’s solely Joint Fee-accredited radiopharmacy community, with 31 radiopharmacies protecting greater than 85% of the inhabitants. Each RLS radiopharmacy homes cutting-edge clear rooms and is totally geared up and aligned to USP , USP and ISO 14644-1 compliance requirements. Each RLS radiopharmacy is led by skilled nuclear pharmacists, who, together with nuclear technicians, in-house couriers and a strong supply fleet, guarantee each SPECT, PET and therapeutic product the corporate provides is meticulously ready, distributed and distributed to the corporate’s greater than 1,500 clients with out fail. For extra info, please go to rls.bio.
About Telix Prescribed drugs Restricted
Telix is a biopharmaceutical firm targeted on the event and commercialization of therapeutic and diagnostic radiopharmaceuticals and related medical units. Telix is headquartered in Melbourne, Australia, with worldwide operations in the US, Europe (Belgium and Switzerland), and Japan. Telix is growing a portfolio of medical and business stage merchandise that goals to handle important unmet medical wants in oncology and uncommon ailments. Telix is listed on the Australian Securities Change (ASX: TLX).
Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (often known as 68Ga PSMA-11 and marketed beneath the model identify Illuccix ®), has been accredited by the U.S. Meals and Drug Administration (FDA)5, by the Australian Therapeutic Items Administration (TGA) 6, and by Well being Canada7. No different Telix product has acquired a advertising and marketing authorization in any jurisdiction.
Go to www.telixpharma.com for additional details about Telix, together with particulars of the newest share worth, bulletins made to the ASX, investor and analyst displays, information releases, occasion particulars and different publications which may be of curiosity. You can too comply with Telix on X and LinkedIn.
Telix Investor Relations
Ms. Kyahn Williamson
Telix Prescribed drugs Restricted
SVP Investor Relations and Company Communications
E-mail: kyahn.williamson@telixpharma.com
Telix Media Relations (U.S.)
Eliza Schleifstein
ES Media Relations
E-mail: eliza@schleifsteinpr.com
Telephone: 917-763-8106
RLS Investor Relations
Mark Elliott
RLS (USA) Inc.
VP Finance and Investor Relations
E-mail: investorrelations@rls.bio
Authorized Notices
It’s best to learn this announcement along with our danger components, as disclosed in our most lately filed studies with the Australian Securities Change (ASX) or on our web site.
The data contained on this announcement isn’t meant to be a suggestion for subscription, invitation or advice with respect to securities of Telix Prescribed drugs Restricted (Telix) in any jurisdiction, together with the US. The data and opinions contained on this announcement are topic to alter with out notification. To the utmost extent permitted by legislation, Telix disclaims any obligation or endeavor to replace or revise any info or opinions contained on this announcement, together with any forward-looking statements (as referred to under), whether or not on account of new info, future developments, a change in expectations or assumptions, or in any other case. No illustration or guarantee, categorical or implied, is made in relation to the accuracy or completeness of the data contained or opinions expressed in the middle of this announcement.
This announcement could include forward-looking statements that relate to anticipated future occasions, monetary efficiency, plans, methods or enterprise developments. Ahead-looking statements can typically be recognized by means of phrases akin to could, anticipate, intend, plan, estimate, anticipate, consider, outlook, forecast and steering, or the damaging of those phrases or different related phrases or expressions. Ahead-looking statements contain recognized and unknown dangers, uncertainties and different components that will trigger our precise outcomes, ranges of exercise, efficiency or achievements to vary materially from any future outcomes, ranges of exercise, efficiency or achievements expressed or implied by these forward-looking statements. Ahead-looking statements are primarily based on Telix’s good-faith assumptions as to the monetary, market, regulatory and different dangers and concerns that exist and have an effect on Telix’s enterprise and operations sooner or later and there will be no assurance that any of the assumptions will show to be appropriate. Within the context of Telix’s enterprise, forward-looking statements could embody, however will not be restricted to, statements about: the initiation, timing, progress and outcomes of Telix’s preclinical and medical trials, and Telix’s analysis and improvement applications; Telix’s means to advance product candidates into, enrol and efficiently full, medical research, together with multi-national medical trials; the timing or probability of regulatory filings and approvals for Telix’s product candidates, manufacturing actions and product advertising and marketing actions; Telix’s gross sales, advertising and marketing and distribution and manufacturing capabilities and techniques; the commercialisation of Telix’s product candidates, if or after they have been accredited; Telix’s means to acquire an ample provide of uncooked supplies at cheap prices for its merchandise and product candidates; estimates of Telix’s bills, future revenues and capital necessities; Telix’s monetary efficiency; developments regarding Telix’s opponents and business; and the pricing and reimbursement of Telix’s product candidates, if and after they’ve been accredited. Telix’s precise outcomes, efficiency or achievements could also be materially completely different from these which can be expressed or implied by such statements, and the variations could also be hostile. Accordingly, you shouldn’t place undue reliance on these forward-looking statements.
©2024 Telix Prescribed drugs Restricted. The Telix Prescribed drugs ®, Illuccix ®, AR™S ® and QIS™ names and logos are logos of Telix Prescribed drugs Restricted and its associates “ all rights reserved.
______
1 Positron emission tomography.
2 Single-photon emission computed tomography.
3 Good Manufacturing Observe.
4 Monetary 12 months ended 31 December 2023.
5 Telix ASX disclosure 20 December 2021.
6 Telix ASX disclosure 2 November 2021.
7 Telix ASX disclosure 14 October 2022.
Supply: Telix Prescribed drugs Restricted
